Immune Pharmaceuticals applies a personalized approach to treating and developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The company’s lead product candidate, bertilimumab, is in clinical development for moderate to severe ulcerative colitis and Crohn’s disease as well as bullous pemphigoid, an orphan auto-immune dermatological condition. Immune’s pipeline also includes NanomAbs, antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics, and AmiKet, a neuropathic pain drug candidate ready for a phase 3 clinical trial. For more information, visit the company’s website at www.immunepharmaceuticals.com.